Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kullback-Leibler divergence for evaluating bioequivalence.

Vladimir Dragalin1, Valerii Fedorov, Scott Patterson

  • 1GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989, USA. vladimir.2.dragalin@gsk.com

Statistics in Medicine
|March 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Informative Futility Rules Based on Conditional Assurance.

Statistics in medicine·2026
Same author

Do We Always Need a New Preference Study? A Scoping Review of Promising Research Areas for Meta-Analyses and Benefit Transfers of Patient Preference Studies.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2025
Same author

Joint modeling of longitudinal endpoints and its applications to trial planning, monitoring and analysis.

Journal of biopharmaceutical statistics·2025
Same author

Designing a Patient Preference Study on Subcutaneous Medical Devices: Incorporating Health Authority Scientific Advice and Patient Perspectives.

Therapeutic innovation & regulatory science·2025
Same author

Bayesian efficient safety monitoring: a simple and well-performing framework to continuous safety monitoring of adverse events in randomized clinical trials.

Journal of biopharmaceutical statistics·2025
Same author

Antibody Persistence and Risk of COVID-19 Infection: Insights from Modeling.

Vaccines·2024
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
See all related articles

This study introduces a new bioequivalence evaluation method using Kullback-Leibler divergence (KLD) to assess average, population, and individual bioequivalence. The KLD method offers a more robust and interpretable alternative to current FDA guidelines for drug formulation comparison.

Area of Science:

  • Pharmacokinetics and Drug Development
  • Biostatistics
  • Regulatory Science

Background:

  • Current bioequivalence assessments often rely on methods with limitations.
  • Measures like average bioequivalence (ABE) do not fully capture population bioequivalence (PBE) or individual bioequivalence (IBE).
  • PBE relates to prescribability, and IBE relates to switchability of drug formulations.

Purpose of the Study:

  • To propose and evaluate a novel methodology for assessing drug bioequivalence.
  • To incorporate measures for average, population, and individual bioequivalence using a unified approach.
  • To address limitations of existing FDA-recommended bioequivalence evaluation metrics.

Main Methods:

  • Utilizing Kullback-Leibler divergence (KLD) to quantify the discrepancy between drug formulation distributions.

Related Experiment Videos

  • Establishing bioequivalence based on the upper bound of a confidence interval for KLD against a regulatory goalpost.
  • Evaluating the KLD method's performance through simulation studies and retrospective analyses, comparing it with FDA-proposed metrics.

    • Main Results:

    • The KLD metric demonstrates desirable properties including hierarchical relationships (IBE => PBE => ABE), metric properties, invariance, multivariate generalization, and broad distribution applicability.
    • Simulation studies indicate the KLD method's viability.
    • Retrospective analyses show KLD as a practical alternative to FDA-proposed metrics for evaluating individual bioequivalence.

    Conclusions:

    • The Kullback-Leibler divergence (KLD) offers a mathematically sound and statistically robust alternative for bioequivalence evaluation.
    • This methodology provides a more comprehensive assessment, encompassing ABE, PBE, and IBE.
    • The KLD method is a viable and interpretable tool for regulatory decision-making in drug formulation comparison.